Start small, think big: Genmab racks up a bispecific development deal with HIV specialist Gilead
Genmab is on a roll. The biotech has inked another high-profile collaboration deal — this time with Gilead — that will put its bispecific antibody tech to work on HIV therapies.
The deal starts small, with Gilead handing over a $5 million upfront and following it up with $277 million-plus in potential milestones, depending on how far Genmab can get. The Danish company is using its DuoBody platform on the deal, which boasts an ability to bind to different targets without losing the therapeutic punch expected from a single antibody.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.